Immunotherapies for Hodgkin's lymphoma.

Yvette L Kasamon, Richard F Ambinder

Open access · greenAbstract readReview

In one paragraph

Review in Critical reviews in oncology/hematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

1.0field-weighted citation impact, top 23% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.Frontiers in oncology · 2012
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yvette L KasamonDivision of Hematologic Malignancies, Johns Hopkins Medical Institutions, Baltimore, MD, USA. ykasamo1@jhmi.edu

Richard F Ambinder

Johns Hopkins University · US

Funding

Treatment of lymphoma by death receptor induced apoptosisP50CA096888 · NCI · JOHNS HOPKINS UNIVERSITY · PI AMBINDER, RICHARD FREDERICK · 2002 to 2009

$13.6M

Adult Hodgkin's Disease and Epstein Barr VirusR01CA095423 · NCI · JOHNS HOPKINS UNIVERSITY · PI AMBINDER, RICHARD FREDERICK · 2002 to 2006

$1.8M

NCI NIH HHS P50 CA096888NCI NIH HHS R01 CA095423

6 · The paper itself

Abstract

Multiple immune evasion strategies characterize the pathobiology of Hodgkin's lymphoma. These must be considered when developing and testing immunotherapeutic approaches for this disease. The clinical experience with adoptive immunotherapy of Epstein-Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed.

Indexed as

ImmunotherapyTumor EscapeAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, NeoplasmCancer VaccinesHerpesvirus 4, HumanHodgkin DiseaseHumansImmunoconjugatesImmunotherapy, AdoptiveKi-1 AntigenRadiotherapy, AdjuvantRituximabAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, NeoplasmCancer VaccinesImmunoconjugatesKi-1 AntigenRituximab

Identifiers

PMID18023356

DOI10.1016/j.critrevonc.2007.10.001

PMCPMC5792053

OpenAlexW2060048926

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.